首页> 美国卫生研究院文献>Pharmaceutics >Analysis of Vipadenant and Its In Vitro and In Vivo Metabolites via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry
【2h】

Analysis of Vipadenant and Its In Vitro and In Vivo Metabolites via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry

机译:液相色谱-四极杆飞行时间质谱法分析维巴达坦及其体外和体内代谢产物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A simple and sensitive liquid chromatography–quadrupole-time-of-flight–mass spectrometric (LC-QTOF-MS) assay has been developed for the evaluation of drug metabolism and pharmacokinetics (PK) properties of vipadenant in rat, a selective A2a receptor antagonist as one of the novel immune checkpoint inhibitors. A simple protein precipitation method using acetonitrile was used for the sample preparation and the pre-treated samples were separated by a reverse-phase C18 column. The calibration curve was evaluated in the range of 3.02 ~ 2200 ng/mL and the quadratic regression (weighted 1/concentration) was used for the best fit of the curve with a correlation coefficient ≥0.997. The in vivo PK studies in rats showed that vipadenant bioavailability was 30.4 ± 8.9% with a low to moderate drug clearance. In addition, in vitro/in vivo metabolite profiles in rat were also explored. Five different metabolites were observed in our experimental conditions and the major metabolites were different between in vitro and in vivo conditions. As far as we know, there has been no report on the development of quantitative methods for its PK samples nor the identification of its metabolites since vipadenant was developed. Therefore, this paper would be very useful to better understand the pharmacokinetic and drug metabolism properties of vipadenant in rat as well as other species.
机译:已开发出一种简单而灵敏的液相色谱-四极杆飞行时间质谱(LC-QTOF-MS)测定法,用于评估维帕替尼在大鼠中的药物代谢和药代动力学(PK)特性,这是一种选择性的A2a受体拮抗剂作为新型的免疫检查点抑制剂之一。使用乙腈的简单蛋白质沉淀方法用于样品制备,并通过反相C18柱分离预处理的样品。在3.02〜2200 ng / mL的范围内评估校准曲线,并使用二次回归(加权1 /浓度)以最佳拟合曲线,相关系数≥0.997。在大鼠体内进行的PK研究表明,维巴多烯的生物利用度为30.4±8.9%,药物清除率低至中度。此外,还研究了大鼠体内/体外代谢产物的概况。在我们的实验条件下观察到五种不同的代谢物,而在体内和体外条件下,主要代谢物也有所不同。据我们所知,自从开发出维巴定剂以来,还没有关于开发其PK样品定量方法或鉴定其代谢物的报道。因此,这篇论文对于更好地了解维帕替尼在大鼠以及其他物种中的药代动力学和药物代谢特性将非常有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号